3E Bioventures Capital
Venture capitalPalo Alto · Seed–Series A · 5 people tracked
Investment thesis
3E Bioventures Capital backs global leading health innovators, focusing on biotech—including new drugs, new modalities, and drug discovery platforms—and TechBio, where biology intersects with technology to disrupt established paradigms. The firm follows a science-driven, entrepreneur-friendly philosophy, collaborating closely with companies and research institutions to develop drugs and products that address significant unmet medical needs. Its name reflects its guiding principles of Expertise, Efficiency, and Execution.
Source: firm website, verified Aug 3, 2026.
Team · 5 people
from public directories
What they invest in
from 30 of 46 portfolio companiesBiotech ×23Healthtech ×18Medical Devices ×14Deep Tech ×10AI & Machine Learning ×8Digital Health ×5Hardware ×4Semiconductors ×2
HQs:United States×17China×4
Who they back
founder profiles across 13 portfolio companiesFounding team size:solo founder×42 founders×63 founders×14+ founders×2
Investments · 46 tracked
founders shown can be your intro pathBy year:2022 · 12020 · 22019 · 22017 · 12015 · 17 dated
C4 Therapeutics develops targeted protein degradation medicines aimed at treating disease.
BiotechCambridge, US
BoardMarc Cohen(Executive Officer, Director)Jason Fisherman(Executive Officer, Director)Miles Stuchin(Director)Bruce Downey(Director)Bihua Chen(Director)William M. Scalzulli(Director)
Co-investorsBain Capital Life SciencesNextech InvestRA Capital
Cytek Biosciences develops high-parametric analytical instruments and software that enable scientists at pharmaceutical companies, contract research organizations, and academic institutions to generate and analyze biological datasets.
BiotechDeep TechHardwareHealthtechMedical DevicesBellevue, US
Wenbin Jiang, Ph.D.(CEO and Chairman of the Board)Wenbin Jiang(Executive Officer, Director)Ming Yan, Ph.D.(Chief Technology Officer)Ming Yan(Executive Officer, Director)Jiecheng Zhang(Director)Allen Poirson(Director)
Co-investorsF-Prime CapitalNorthern Light Venture Capital
Profusa develops injectable hydrogel biosensors and AI-driven health platforms that enable real-time measurement of body chemistry from within tissue.
AI & Machine LearningDigital HealthHealthtechMedical DevicesSan Francisco, US
Bill Fawcett(Co-founder)Natalie Wisniewski(Executive Officer, Director)Ben Healy(CEO)Ben Hwang(Executive Officer, Director)
BoardQianye Karen Liu(Director)Thomas Gutshall(Director)
Co-investorsAsset Management CompanyAtinum Investment Co. Ltd.BioVentures
Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals.
BiotechDeep TechSemiconductorsSouth San Francisco, US
Emily Marine Leproust(Executive Officer, Director, Promoter)William Charles Banyai(Executive Officer, Director, Promoter)Bill James Peck(Executive Officer, Promoter)Emily Leproust(Founder)in
BoardKeith Crandell(Director)Paul Conley(Director)in
Co-investors+ND CapitalARCH Venture PartnersAsset Management CompanyBay City CapitalBlack Opal VenturesDentsu Ventures+7 more
Arnatar develops a next-generation RNA discovery platform called DARGER that combines gene silencing and gene upregulation technologies for oligonucleotide therapeutics.
AI & Machine LearningBiotechDeep Tech
Dr. Xuehai Liang(Founder)Dr. Yanfeng Wang(Founder & Chief Operating Officer)
Co-investorsF-Prime CapitalApricot CapitalEight Roads VenturesGaorong VenturesLegend StarNew Alliance Capital
Dermaliq Therapeutics is a specialty pharmaceutical company developing topical dermatology therapies and medical skin care products based on its proprietary hyliQ drug-delivery platform, with a lead pipeline focused on hair loss conditions such as androgenetic alopecia and alopecia areata.
BiotechHealthtechWilmington, US
Oliver Schlüter(CFO & Co-Founder)Betsy Hughes-Formella(CSO & Co-Founder / R&D Consultant)Christian Roesky(CEO & President)
ProNovo Therapeutics is a biotechnology company developing precision small-molecule therapeutics for neuropsychiatric disorders, including Major Depressive Disorder and Schizophrenia.
BiotechHealthtechMental Health
Guang Chen(Founder, Board Director & Chief Scientific Officer)inXiaohu Deng(Co-Founder & CEO)inScott Thompson(Co-Founder & Chair of Scientific Advisory Board)in
Co-investorsGaorong Ventures
An innovative biopharmaceutical company focused on developing therapies for chronic kidney disease across multiple clinical stages, with a pipeline of eight products covering conditions such as hyperphosphatemia, renal anemia, IgA nephropathy, and diabetic kidney disease.
BiotechDigital HealthHealthtechMedical DevicesShanghai, CN
Co-investorsLAVLilly Asia VenturesQuan CapitalSherpa Healthcare Partners
BiotechHouston, US
Amato Giaccia(Director)Rudy Howard(Chief Financial Officer)Robert B. Geller(Chief Medical Officer)Gail McIntyre(Chief Executive Officer)Leonard Scott Dove(Chief Operating Officer)Joshua Brumm(Executive Officer)
Co-investorsAdvent Life Sciences
Reimagining RNA medicines to silence disease drivers or restore missing function.
Avirmax is a preclinical-stage biopharmaceutical company developing AAV-based genetic medicines to treat chronic and degenerative ocular diseases.
BiotechDeep TechMedical DevicesHayward, US
Haifeng Chen(Director and Treasurer of the Issuer)Shengjiang Liu(Executive Officer, Director)
BoardYu Fang(Director of the Issuer)Qianye Karen Liu(Director of the Issuer)Nancy Chang(Director of the Issuer)
Co-investorsBioVentures
Cognition Therapeutics is a clinical-stage biotechnology company developing zervimesine (CT1812), an investigational once-daily oral small-molecule therapy designed to protect brain synapses by blocking toxic protein oligomers.
BiotechHealthtechPittsburgh, US
Susan Catalano(Executive Officer, Director)Harold Safferstein(Executive Officer, Director)
BoardNada Jain(Director)Franz Hefti(Director)Robert Gailus(Director)Mark Breedlove(Director)
Co-investorsAtlanta Technology AngelsHouston Angel NetworkiNetworksDolby Family Ventures
Cullgen is a privately held biopharmaceutical company developing first-in-class drugs based on its uSMITE™ (small-molecule induced ubiquitin-dependent target elimination) targeted protein degradation platform, which uses the ubiquitin-proteasome system and E3 ubiquitin ligases to target disease-causing proteins that conventional small-molecule drugs cannot reach.
BiotechDeep TechHealthtechMedical Devices
Ying Luo(CEO)
Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.
AI & Machine LearningBiotechDeep TechBoston, US
Richard Young, Ph.D.(Director)Anthony Hyman, Ph.D.(Director)Tony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)Ameet Nathwani, M.D.(Executive Officer, Director)
Co-investorsARCH Venture PartnersEcoR1 CapitalSamsara BioCapital6 Dimensions CapitalGeneral CatalystInnovation Endeavors+5 more
Eaglenos develops smart healthcare technologies, focusing on precision testing and personalized health management.
Digital HealthHealthtechMedical DevicesNanjing, CN
Innovative ocular therapeutics for China and global markets.
Co-investorsCenova CapitalQuan Capital
Epimab Biotherapeutics is a clinical-stage biopharmaceutical company specializing in the development of bispecific antibodies using proprietary technology platforms including FIT-Ig® and MAT-Fab.
BiotechHealthtechMedical DevicesShanghai, CN
Wu Chenbing(Founder/Expert)
Co-investorsDecheng CapitalShangBay Capital LLCTCG LabsSherpa Healthcare Partners
The company develops flagship products for medical and industrial markets, focusing on building differentiated, IP-protected features and trade secrets.
Deep TechHardwareMedical Devices
Galaxy Brain Scientific is a neuroscience technology company developing a platform for individualized brain functional mapping and non-invasive precision neuromodulation.
BiotechDeep TechMedical Devices
Digital ELISA protein-detection platform with ultra-high sensitivity, throughput and dynamic range.
Genotix develops single-molecule detection technology to digitally characterize and quantitate biomarkers, aiming to reveal early indicators of disease.
BiotechHealthtechMedical Devices
Targeting intersections for precision immunotherapy, especially in antigen presentation.
Advancing a molecule to treat diseases associated with excess body fat including NASH, Prader-Willi syndrome, and antipsychotic drug-induced weight gain.
Lipidio Pharma is a drug development company that acquires molecules with unrealized therapeutic potential and advances them through preclinical and clinical development toward approval or exit.
BiotechHealthtechSan Diego, US
James Mackay(Co-Founder)David Bullough(Director)Daniel Petree(Director)J. Gordon Foulkes(Executive Officer, Director)
LumiThera develops the Valeda Light Delivery System, an FDA-authorized photobiomodulation (PBM) device that applies multiple light wavelengths to treat early and intermediate dry age-related macular degeneration (AMD).
BiotechHealthtechMedical DevicesPoulsbo, US
Tracy Puckett(Executive Officer)Clark Tedford(Executive Officer, Director)Scott Bradley(Executive Officer)Duane Morrison(Executive Officer)Cindy Croissant(Executive Officer)Ryan Montecucco(Executive Officer)
Co-investorsLife Sciences Greenhouse InvestmentsImagine VenturesKeiretsu Capital
Focused on lysosomal ion channel disease biology.
Mediaspace is a digital agency that designs and builds custom Squarespace websites and provides SEO, digital marketing strategy, and digital advertising services.
AdTechAdvanced ManufacturingAI & Machine LearningData & InfrastructureDigital HealthEnterprise SoftwareHardwareHealthtechMarketing TechMedical DevicesSemiconductorsAtlanta, US
John G. Edwards(Executive Officer, Director)John Jacobi(Executive Officer)Sri Peruvemba(Executive Officer)Francois Jeanneau(Executive Officer, Director)Linda Ara(Executive Officer)Michael Vestel(Executive Officer)
Co-investorsKeiretsu ForumLife Sciences Greenhouse InvestmentsToba CapitalVivo Capital
Developing small-molecule therapeutics targeting common disease mechanisms to restore brain health.
Super-resolution microscopic imaging platform originating from a Nobel Prize winner's laboratory.
Company from Harvard Medical School and MIT McGovern Institute aiming to solve brain disorders.
OncoC4 is a clinical-stage biopharmaceutical company developing immunotherapy treatments for cancer patients, based on research by its immunologist founders.
BiotechHealthtechRockville, US
Yang Liu(Co-founder)Pan Zheng(Co-founder)Martin Devenport(Executive Officer)Michael Flaschen(Director)
Co-investorsHM Venture Partners
First-in-class biologic drug targeting the CD24-Siglec innate immunity signaling pathway.
BiotechRockville, US
Pan Zheng(Executive Officer)Yang Liu(Executive Officer, Director)Martin Devenport(Executive Officer)
BoardMiao Hong(Director)Karen Liu(Director)inKun-Liang Guan(Director)
Co-investorsHM Venture Partners
Advancing precision therapeutics for neuropsychiatric disorders.
Quadriga Biosciences is developing QBS72S, a chemotherapeutic drug candidate that uses the L-type Amino Acid Transporter 1 (LAT1) to cross the blood brain barrier and enter cancer cells, where it forms DNA interstrand cross-links to kill the cells.
BiotechHealthtech
Developing a cure for ADPKD patients.
Biotechnology research organization (est. 2016) focused on uric acid metabolism, inflammatory pain, and gout metabolic syndrome.
Shanton Pharma is a clinical-stage biotech company developing drugs for gout, hyperuricemia, and pruritus.
BiotechHealthtech
Smartlens develops wearable microfluidic devices and AI-powered platforms for remote monitoring and diagnosis of anterior segment eye diseases, particularly glaucoma.
AI & Machine LearningDigital HealthHealthtechMedical Devices
Co-investorsAmbit Health Ventures
Subtle Computing (legally Skywalk, Inc.) makes wireless earbuds sold directly at subtle.co and through authorized resellers, along with a companion mobile app.
AI & Machine LearningConsumerDirect to ConsumerHardware
Tyler Chen(Founder)in
Co-investorsAbstract VenturesEntrada VenturesInception Studio CapitalSLVCBRVHike Ventures+2 more
Subtle Medical develops deep learning software for medical imaging that enables faster and safer image acquisition on existing scanners for healthcare providers and imaging centers.
AI & Machine LearningHealthtechMedical Devices
Greg Zaharchuk(Co-founder, MD, Ph.D., Neuroradiologist and Professor at Stanford)inEnhao Gong(Co-founder, Ph.D., Deep Learning Scientist)in
Co-investorsAtinum Investment Co. Ltd.Bessemer Venture PartnersBreyer CapitalDCVC (Data Collective)Foothill VenturesFusion+2 more
Nasdaq: TWST.
Exits · 4
IPOs and acquisitions across the tracked portfolioC4 TherapeuticsNASDAQ: CCCCCytek BiosciencesNASDAQ: CTKBProfusaNASDAQ: PFSATwist BioscienceNASDAQ: TWST
Portfolio news
latest coverage across their companiesArnatar Therapeutics · dakota.com · Aug 18, 2026
C4 Therapeutics · stocktitan.net · Aug 14, 2026
Alebund · fiercebiotech.com · Aug 12, 2026
Profusa · investing.com · Jun 10, 2026
Subtle · pulse2.com · Jun 3, 2026
Dewpoint Therapeutics · trial.medpath.com · Sep 11, 2025
Frequently asked questions
- How many investments has 3E Bioventures Capital made?
- 3E Bioventures Capital has 42 tracked investments, 1 of which have exited via acquisition or IPO.
- What stage does 3E Bioventures Capital invest at?
- 3E Bioventures Capital invests at the Seed, Series A stages.
- What sectors does 3E Bioventures Capital focus on?
- 3E Bioventures Capital focuses on AI & Machine Learning, Biotech, Deep Tech, Healthtech, Medical Devices.
- Where is 3E Bioventures Capital located?
- 3E Bioventures Capital is headquartered in Palo Alto, US.
- Does 3E Bioventures Capital lead rounds?
- 3E Bioventures Capital typically participates in rounds rather than leading them.
- Who does 3E Bioventures Capital co-invest with?
- 3E Bioventures Capital most often shares deals with ARCH Venture Partners, Asset Management Company, F-Prime Capital, among 38 tracked co-investors.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Granatus Ventures is a venture capital firm that backs startups worldwide leveraging Armenia's potential as an emerging technology hub.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.